Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Results in CP are better in patients treated early after the onset of the disease with
respect to late CP . To date, the early McR rate to imatinib is clearly higher in low and
intermediate risk versus high risk (88 and 84% versus 65%). High dose of imatinib, as shown
in phase I-III trials may offer the possibility to increase the response rate of patients
belonging to this risk category.